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Abstract
Background: Interferon-a (IFN-a) treatment suppresses HIV-1 viremia and reduces the size of the HIV-1 latent reservoir.
Therefore, investigation of the molecular and immunologic effects of IFN-a may provide insights that contribute to the
development of novel prophylactic, therapeutic and curative strategies for HIV-1 infection. In this study, we hypothesized
that microRNAs (miRNAs) contribute to the IFN-a-mediated suppression of HIV-1. To inform the development of novel
miRNA-based antiretroviral strategies, we investigated the effects of exogenous IFN-a treatment on global miRNA
expression profile, HIV-1 viremia, and potential regulatory networks between miRNAs and cell-intrinsic anti-HIV-1 host
factors in vivo.
Methods: Global miRNA expression was examined in longitudinal PBMC samples obtained from seven HIV/HCV-coinfected,
antiretroviral therapy-naı¨ve individuals before, during, and after pegylated interferon-a/ribavirin therapy (IFN-a/RBV). We
implemented novel hybrid computational-empirical approaches to characterize regulatory networks between miRNAs and
anti-HIV-1 host restriction factors.
Results: miR-422a was the only miRNA significantly modulated by IFN-a/RBV in vivo (p,0.0001, paired t test; FDR,0.037).
Our interactome mapping revealed extensive regulatory involvement of miR-422a in p53-dependent apoptotic and
pyroptotic pathways. Based on sequence homology and inverse expression relationships, 29 unique miRNAs may regulate
anti-HIV-1 restriction factor expression in vivo.
Conclusions: The specific reduction of miR-422a is associated with exogenous IFN-a treatment, and likely contributes to the
IFN-a suppression of HIV-1 through the enhancement of anti-HIV-1 restriction factor expression and regulation of genes
involved in programmed cell death. Moreover, our regulatory network analysis presents additional candidate miRNAs that
may be targeted to enhance anti-HIV-1 restriction factor expression in vivo.
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Introduction
Induction of interferon-a (IFN-a) expression is a critical first
step in the defense against a range of viral pathogens [1,2]. Several
studies have demonstrated that IFN-a treatment potently
suppresses HIV-1 viremia in chronically infected individuals [3–
6]. A provocative recent report demonstrated that IFN-a
treatment results in sustained viral suppression in the absence of
antiretroviral therapy (ART) and significant reduction in the size
of the HIV-1 reservoir in chronically-infected individuals [7,8]. A
related analysis of the effects of IFN-a/ribavirin therapy on the
HIV-1 latent reservoir in HIV/HCV-coinfected individuals
reported a similar, significant reduction in reservoir size [9].
These studies collectively demonstrate that IFN-a molecular
pathways may be exploited to attack the HIV-1 latent reservoir
and achieve HIV-1 eradication.
In contrast to exogenous IFN-a treatment, endogenous IFN-a
production and associated gene expression patterns are curiously
often associated with rapid HIV-1 disease progression, high viral
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load and persistent inflammation rather than beneficial disease
outcomes [10,11]. This paradox is mirrored in recent studies of
LCMV infection suggesting that IFN-a is associated with both
beneficial and detrimental disease outcomes, and disease progres-
sion is governed by the overall balance between the various,
diverse effects of type I interferon [12,13]. Focused analyses of
IFN-a molecular pathways in vivo may allow us to identify specific
mechanisms underlying the beneficial effects of IFN-a treatment
on the control and clearance of viral infection. IFN-a treatment
has been previously associated with an increase in perforin and
granzyme A expression by natural killer (NK) cells in HIV-1-
infected individuals, suggesting that enhanced NK-mediated anti-
HIV-1 cytolytic activity may contribute to viral suppression [14].
Our group recently published data suggesting that several host
restriction factors including BST-2/tetherin and members of the
tripartite motif (TRIM) and APOBEC3 families play critical roles
in the interferon-mediated suppression of HIV-1 viremia in
chronically-infected individuals [15,16] and in the control of
HIV-1 in vivo in the absence of antiretroviral therapy (ART) [17].
In this study, we hypothesize that microRNAs (miRNAs)
contribute to the IFN-a-mediated suppression of HIV-1 by
repressing HIV-1 protein translation directly, or by regulating
the gene expression of host factors affecting HIV-1 replication and
persistence in vivo.
miRNAs are a class of small non-protein-coding RNAs
(approximately 22 nucleotides in length) that pair with specific
‘‘target’’ messenger RNAs (mRNAs) and play a significant role in
regulating gene expression by binding to mRNAs, thereby
repressing translation or degrading the mRNA altogether [18].
Solitary miRNAs often regulate expression of multiple genes with
related functions; therefore, changes in expression levels of a single
miRNA can broadly affect a gene network and modify complex
biological processes [18]. miRNAs play a pivotal role in many
biological processes, including cellular differentiation and prolif-
eration [19]. Aberrant miRNA levels are associated with a number
of disease states including several types of cancer, in which
miRNAs can act as tumor suppressors and oncogenes [20].
miRNAs of viral and host origin may influence host-virus
interaction by acting as direct modulators of viral replication, as
factors affecting viral susceptibility, and as indirect modulators of
cellular genes that influence viral propagation [21–23]. In the
context of HIV-1 infection, a main challenge is to determine the
specific roles of the expanding inventory of human miRNAs in
HIV-1 pathogenesis, including the functional consequences of
miRNA-mRNA interactions [24]. Human miR-28, miR-125b,
miR-150, miR-223, and miR-382 target the 39 UTR of HIV-1
transcripts, interfering with HIV-1 accessory gene expression
potentially shifting productive infection into latency in resting
CD4+ T lymphocytes [25]. The difference in expression levels of
several anti-HIV-1 miRNAs in monocytes and macrophages
correlates with cellular permissibility to HIV-1 infection in vitro
[26]. A recent report suggests that miR-148 regulates the
expression of HLA-C at the host cell surface, and this regulatory
activity is correlated with control of HIV-1 replication [27]. Taken
together, these observations suggest that studying natural expres-
sion levels of pro- and anti-HIV-1 miRNAs may prove valuable in
understanding susceptibility to infection, and miRNA manipula-
tion may constitute a promising anti-HIV strategy in the future.
Recent data suggest that type I interferon modulates cellular
miRNA profile as an antiviral mechanism against hepatitis C virus
[28]. The relevance of miRNA to the potent IFN-a-mediated
suppression of HIV-1, however, remains to be addressed and is the
focus of this study.
IFN-a monotherapy is not typically administered to HIV-1-
monoinfected individuals. Combination therapy with pegylated
IFN-a and ribavirin (IFN-a/RBV) is commonly used to treat
HCV infection [4]. In this study, we analyzed longitudinal clinical
specimens from IFN-a/RBV-treated, ART-naive HIV/HCV-
coinfected individuals to evaluate the role of miRNAs in the
suppression of HIV-1 by IFN-a in vivo.
Methods
Subjects and specimen processing
Longitudinal samples were collected from seven HIV/HCV-
coinfected individuals enrolled in the Swiss HIV Cohort Study
([SHCS], www.shcs.ch) [29] who underwent IFN-a/RBV treat-
ment (Table S1). All subjects had PBMC samples available before,
during and after IFN-a/RBV treatment (a post-treatment sample
was not available for Subject A), were ART-naı¨ve, and had
detectable HIV-1 RNA at baseline. The same collection of
samples was analyzed in two recent publications from our group
that characterized the role of retroviral restriction factors in the
IFN-a-mediated suppression of HIV-1 in vivo [15,16], and gene
expression data from these prior studies were included in miRNA-
mRNA network analyses presented in this report. The research
was approved by the institutional review boards at each of the
Swiss HIV Cohort Study sites where samples were collected:
University Hospital Basel, University Hospital Bern, University
Hospital Zurich, and Canton Hospital, St. Gallen. All human
participants gave written informed consent.
Cellular microRNA expression profiling
Total RNA was extracted from PBMC using TRIzol reagent
(Invitrogen). miRNA expression was determined by applying the
Megaplex Pools protocol (Applied Biosystems). 300 ng of RNA
from PBMCs of the seven patients (pre, during, and post time
points) was reverse transcribed using the TaqMan MicroRNA
reverse transcription kit in combination with the Megaplex RT
Primers Pool A that allows the analysis of 377 human miRNAs
which represent the most rigorously studied human miRNAs or
Megaplex RT Primers Pool B that allows the analysis of 377 newly
discovered human miRNAs and endogenous controls. The
following cycling conditions were used: 40 cycles at 16uC for
2 minutes, 42uC for 1 minute and 50uC for 1 second followed by
1 step at 85uC for 5 minutes. Reverse transcription was followed
by a preamplification of the miRNA cDNA target (2.5 mL) using
TaqMan PreAmp Master Mix kit and Megaplex PreAmp Primers
Pool A or B (Applied Biosystems). The following cycling conditions
were applied: denaturation for 10 minutes at 95uC, 1 step at 55uC
for 2 minutes followed by 2 minutes at 72uC, and 12 cycles (95uC
for 15 seconds, 60uC for 4 minutes). According to manufacturer’s
instructions, the preamplified cDNA product was loaded onto
TaqMan MicroRNA Array A or TaqMan MicroRNA Array B
after mixing with water and TaqMan Universal PCR Master Mix,
with Uracil-DNA glycosylase (UNG). The following real-time
PCR protocol was used: 2 min at 50uC, 10 min at 95uC, 40 cycles
of (30 s at 95uC and 1 min at 60uC). Real time PCR reactions
were performed on an ABI ViiA 7 Real-Time PCR System
(Applied Biosystems). The results were analyzed using ABI ViiA 7
Real-Time PCR software (Applied Biosystems), based on the
comparative Ct method (delta deltaCt). The amplification signal
was checked on each sample by ABI ViiA 7 Real-Time PCR
System software. Data were normalized using a modified global
mean normalization strategy based on common targets. The
global mean on common targets strategy calculates normalization
factors based on the geometric mean of the Relative Quantities
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(RQs) of all genes that are measured in all samples. It is a variant
on the global mean normalization strategy and has proven to be
the most accurate and sensitive approach to analyze high-
throughput miRNA profiles [30,31]. Analyses were restricted to
miRNAs that were detectable in a minimum of 80% of samples
(i.e. miRNAs that were expressed in at least 16 out of the 20
samples analyzed in this study) [32]; 289 miRNAs were chosen for
subsequent analysis based on this threshold criterion.
In-vitro analysis of IFN-a treatment effects
PBMCs were collected from eight healthy (HIV- and HCV-
negative) donors. All donor samples are routinely tested for a
comprehensive panel of bloodborne pathogens upon collection
including HIV, HCV and HBV using ultrasensitive PCR (nucleic
acid test yield) and serology. The healthy donor study protocols
were approved by the UCSF Committee on Human Research.
CD4+ T cells were isolated using bead-based negative selection
(STEMCELL Technologies). Cells were plated at a million cells
per well and treated with either 5 U/ml of IFN-a-A2 (R&D
Systems) or media as a negative control. The expression of miR-
422a was measured after 24 hours of stimulation using Taqman
primers and probes (Life Technologies).
Quantitative PCR measurement of MLH1 and TP53 mRNA
expression
RNA from PBMCs was transcribed into cDNA using the
SuperScript VILO cDNA Synthesis Kit (Invitrogen). Quantitative
real-time PCR measuring MLH1 and TP53 using Taqman real
time PCR was performed using the ABI ViiA 7 Real-Time PCR
System. Raw cycle threshold (Ct) numbers of amplified gene
products were normalized to the housekeeping gene ribosomal
protein, large, P0 (RPLP0) to control for cDNA input amounts.
RPLP0 was chosen as the housekeeping gene based on our
previous analyses of the same set of samples [16]. We previously
tested a panel of six housekeeping genes (GAPDH, 18S, ACTB,
PPIA, RPLP0, and UBC). The GeNorm algorithm [33] identified
RPLP0 as the most stably expressed housekeeping gene. Fold
induction was determined using the comparative Ct method [33].
Statistical analysis
We identified differentially expressed miRNAs between pre-,
during, and post-IFN-a/RBV time points using paired t-tests for
each miRNA. To adjust for multiple comparisons, false discovery
rates (FDR) were computed using the Benjamini-Hochberg
procedure [34]. Viral load values were log10 transformed, and
miRNA values were global-normalized and then log10 trans-
formed. The missing values for each miRNA were imputed by the
minimum detected value minus 0.5. After log10 transformation
and imputation, the within-group standard deviations (median
across microRNAs) were 0.79 for peg-IFN-a/RBV timepoints,
and 0.88 for during-IFN-a/RBV timepoints.
miRNA interactome characterization
Lists of restriction factors and miRNAs that were modulated by
exogenous IFN-a/RBV treatment were uploaded to the Ingenuity
Pathway Analysis (IPA) tool (Ingenuity Systems, www.ingenuity.
com), and were analyzed based on the IPA library of canonical
pathways. IPA was implemented to create a genetic interaction
network depicting known experimentally validated relationships.
miRNA-mRNA network inference
We used two variables to generate a network between miRNAs
and anti-HIV-1 restriction factor mRNAs: 1) inverse expression
relationships between a given miRNA-mRNA pair, and 2)
significant sequence homology between a given miRNA seed
region and a restriction factor 39 UTR. miRNA-mRNA inverse
expression relationships were determined using the Pearson
correlation coefficient (p-value,0.05, rho#0.07). miRNA-mRNA
sequence homology was determined by using blastn (http://blast.
ncbi.nlm.nih.gov/) with word size 4, alignment length $5, and no
mismatches allowed. We required reverse-complementing matches
between miRNAs and mRNAs, with E-value cutoff #1.
Results and Discussion
We examined the effects of exogenous IFN-a treatment on
PBMC miRNA profile, focusing on seven subjects before, during
and after IFN-a/RBV therapy (Table S1). A total of 754
established miRNA targets were surveyed in PBMCs. Based on
our threshold criterion (detectable expression in a minimum of
80% of samples), 289 miRNAs were chosen for subsequent
analysis. We aimed to identify particular miRNA variants that
were up- or down-regulated in PBMCs during IFN-a/RBV
treatment consistently across individuals. IFN-a/RBV did not
significantly affect expression levels of miRNA machinery genes
(Fig. S1) suggesting that observed effects of IFN-a/RBV on
particular miRNAs were specific in nature rather than the
consequence of nonspecific shifts in global miRNA production.
Of all 754 miRNAs measured, 45 miRNAs were significantly
modulated by IFN-a/RBV in vivo, based on a paired t test and an
uncorrected significance cutoff of p,0.05 (Fig. 1, Table S2).
Twelve miRNAs in this list have been previously associated with
HIV-1 infection (Table S2). However, due to the large number of
miRNAs surveyed, accounting for multiple comparisons is
imperative. After correcting for false discovery rate to account
for multiple comparisons, only one miRNA out of the 45 initially
identified, miR-422a, was significantly modulated by IFN-a/RBV
in vivo using our highly stringent statistical criteria (p,0.0001,
paired t test; FDR,0.037) (Fig. 2A). We then performed a
controlled in vitro experiment in the absence of ribavirin co-
administration and HIV or HCV infection to determine if IFN-a
treatment suppresses miR-422a expression in CD4+ T cells, the
principal target cells of HIV-1 infection in peripheral tissues. This
experiment was conducted to evaluate the possibility that miR-
422a modulation by IFN-a occurs within the target cell and may
therefore play a role in determining cell-intrinsic susceptibility to
HIV-1 infection. CD4+ T cells were negatively selected from fresh
peripheral blood collected from eight HIV- and HCV-uninfected
donors and treated with IFN-a in vitro. IFN-a treatment
significantly suppressed miR-422a in CD4+ T cells in vitro
(p = 0.016), extending the primary result of our in vivo expression
profiling experiment (Fig. 2B).
We next sought to determine if any miRNAs exhibited
significant correlations with HIV-1 viral load in our study
population. Results are presented in Table 1. Several of the
miRNAs exhibiting correlations with plasma viremia have been
previously associated with HIV-1. The copy numbers of seven
miRNAs were significantly correlated with baseline, pre-IFN-a/
RBV HIV-1 viral load (p,0.05, Spearman’s rank): miR-29a,
miR-101, miR-195, miR-25#, miR-491, miR-503, and miR-885.
The copy numbers of six miRNAs were correlated with HIV-1
viral load during IFN-a/RBV: miR-138, miR-Let-7e, miR-10a,
miR-145#, miR-31, and miR-589. Lastly, log HIV-1 viral load
reduction during IFN-a/RBV therapy was significantly correlated
with fold change of the following four miRNAs: miR-30e-3p, miR-
148b#, miR-30d, and miR-589 (IFN-a/RBV treatment reduced
plasma viral load by 0.80 (60.33) log10 copies/ml during
Interferon-a/Ribavirin Modulation of Anti-HIV-1 MicroRNAs In Vivo
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treatment, and viremia typically returned to approximate pre-
treatment levels following therapy). Of particular relevance in
these lists, miR-29a and miR-138 have been demonstrated to
target HIV-1 directly [35], and both miRNAs demonstrated a
negative correlation with HIV viral load in the current study.
Based on our data suggesting that miR-422a is the only miRNA
that is significantly modulated by IFN-a in vivo in PBMCs, we
performed a comprehensive search of the literature to identify
established gene targets that are known to be regulated by miR-
422a. To the best of our knowledge, there are only two
experimentally verified regulatory targets of miR-422a: CYP7A1,
a gene involved in regulation of bile acid synthesis in the liver [36],
and MLH1, a gene involved in DNA mismatch repair that is a
MutLa component [37]. According to a study by Mao et al [37],
miR-422a negatively regulates the expression of MLH1. Overex-
pression of MLH1 induces apoptosis by blocking transcription on
damaged DNA templates, resulting in p53 induction [38,39]. The
IFN-a-mediated suppression of miR-422a observed in our
preliminary experiments would be expected to result in increased
expression of MLH1, which in turn should elevate p53 expression,
resulting in the induction of apoptosis. We sought to confirm these
predicted relationships using our existing PBMC specimens from
the seven SHCS patients, by measuring the mRNA expression of
MLH1 and TP53 (the gene encoding p53) before and during IFN-
a/RBV treatment. As predicted, both MLH1 and TP53
expression were elevated during the IFN-a/RBV treatment period
(Fig. 2C and 2D), and a near perfect correlation was observed
between the induction of the two genes (Fig. 2E). Although this
does not represent direct evidence of a regulatory relationship
between miR-422a and MLH1 (and TP53), the observed
expression patterns are compatible with this regulatory scenario
and consistent with the published literature.
We aimed to expand our understanding of the miR-422a
interactome beyond direct experimentally-validated relationships
using a combination of experimental and bioinformatic tech-
niques. We hypothesized that IFN-a-modulated miRNAs suppress
HIV-1 replication by enhancing the expression of anti-HIV-1 host
restriction factors. We recently characterized the mRNA expres-
Figure 1. Heat map representing effects of IFN-a/RBV treatment on the expression of individual miRNAs. 45 miRNAs were significantly
modulated by IFN-a/RBV in vivo, based on a paired t test and an uncorrected significance cutoff of p,0.05. Relative copy numbers of each miRNA are
reported. Blue color indicates #23 SD from the mean, red indicates $3 SD from the mean, and white represents the mean. Asterisks indicate
previously established association with HIV-1.
doi:10.1371/journal.pone.0109220.g001
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sion of all established anti-HIV-1 host restriction factors in our
collection of longitudinal SHCS samples, demonstrating that IFN-
a treatment significantly induces several restriction factors in vivo
[15,16]. We exploited our previously generated gene expression
data to simultaneously visualize IFN-a effects on miRNA and
restriction factor mRNA profiles in vivo. Our visualization
demonstrated that global miRNA expression was typically
suppressed by IFN-a treatment, while restriction factors were
typically induced (Fig. 3A). The distribution of data was highly
and significantly skewed; miRNAs predominantly occupied the
upper-left quadrant (representing suppression during IFN-a
treatment and rebound to approximate baseline levels post-
treatment), while restriction factor mRNAs predominantly occu-
pied the lower-right quadrant (representing induction during IFN-
a treatment and rebound to approximate baseline levels post-
treatment). Although these correlative data do not prove that
negative regulatory relationships exist between miRNAs and
restriction factor mRNAs, the observed pattern is compatible,
provocative, and worthy of further consideration.
We next implemented Ingenuity Pathway Analysis (IPA)
software to perform integrative bioinformatic analyses of our
miRNA, restriction factor, MLH1 and TP53 mRNA profiles
within the context of gene regulatory networks. By merging our
expression data from SHCS subjects with the Ingenuity Knowl-
edge Base, IPA assembled a rich genetic interaction network
depicting known experimentally validated relationships (Fig. 3B).
There are a few prominent features within the IPA network that
warrant mention. First, in addition to the previously known
relationship with MLH1, miR-422a is predicted to directly
regulate TP53 and the tripartite motif (TRIM) family anti-HIV-
1 restriction factors TRIM19 (PML) and TRIM22. This
prediction is based on sequence homology between the miR-
422a seed region sequence and the 39 UTR of TP53, TRIM19
(PML) and TRIM22. In alignment with this prediction, both
TRIM19 (PML) and TRIM22 are induced by IFN-a/RBV
according to our published data [16]. In addition to putative
antiviral functions, TRIM19 (PML) is a potent driver of DNA
damage-induced apoptosis, and physically interacts with p53
in vitro and in vivo. PML acts as a transcriptional co-activator
with p53 and potentiates the antiproliferative downstream effects
of p53 [40]. Second, TP53 is the epicenter of the miR-422a
genetic interaction network, exhibiting numerous direct and
indirect connections with host restriction factors. Accordingly,
IFN-a has been shown to enhance the transcription of p53 target
Figure 2. miR-422a is modulated by IFN-a treatment. (A) Expression of miR-422a in PBMC in vivo before, during and after IFN-a/RBV treatment
(labeled as ‘‘Rx’’). Error bars represent SEM. P-value was obtained using a paired t-test and FDR is reported. (B) Effects of IFN-a on the expression of
miR-422a in CD4+ T cells in vitro; cells were plated at a million cells per well and treated with either 5 U/ml of IFN-a or media as a negative control. (C)
Expression of MLH1 in PBMC in vivo before, during, and after IFN-a/RBV treatment. (D) Expression of TP53 in PBMC in vivo before, during, and after
IFN-a/RBV treatment. Error bars represent SEM. P-values were obtained using paired Wilcoxon tests. (E) Correlation between TP53 fold induction and
MLH1 fold induction in PBMC in vivo during IFN-a/RBV treatment. P-value was obtained using Spearman’s rank test.
doi:10.1371/journal.pone.0109220.g002
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genes and p53-dependent apoptosis, and can directly induce
expression of p53 [41]. Lastly, the gamma interferon-inducible
gene IFI16 appears in the network. IFI16 has recently been
characterized as a DNA sensor that plays a critical role in
triggering the caspase 1-mediated pyroptosis of abortively-infected
cells [42], which may be a principal mechanism underlying CD4
T cell depletion in HIV-1-infected individuals [43]. Taken
together, the IFN-a-suppressed miRNA miR-422a is embedded
in a rich interactome associated with both control of viral
replication and apoptotic induction.
To complement our focused analyses of miR-422a, we
developed and implemented a computational approach to infer
regulatory networks between the entire repertoire of surveyed
miRNAs and the mRNA expression of anti-HIV-1 restriction
factors observed in our IFN-a/RBV-treated SHCS subjects. Our
approach is derived from a similar experiment used to examine
miRNA-mRNA pairs within the context of HCV infection [44].
Table 1. Correlations between miRNA and HIV-1 viral load.
microRNA Spearman r p value R square Previously associated with HIV? Y/N [ref]
Correlations between pre-IFN-a/RBV miRNA relative copy number and HIV-1 viral load.
miR-25# 0.919 0.007 0.393 N
miR-885-5p 0.857 0.024 0.888 N
miR-195 20.821 0.034 0.426 Y [55]
miR-29a 20.786 0.048 0.635 Y [56,57]
miR-101 20.786 0.048 0.244 Y [58]
miR-503 20.786 0.048 0.210 Y [59]
miR-491-5p 20.786 0.048 0.191 N
Correlations between miRNA relative copy number and HIV-1 viral load during IFN-a/RBV.
miR-145# 0.883 0.015 0.696 N
miR-138 20.857 0.024 0.746 Y [35]
miR-10a 20.821 0.034 0.406 N
miR-31 20.786 0.048 0.755 Y [59,60]
miR-589 20.786 0.048 0.536 N
let-7e 20.786 0.048 0.507 Y [61]
Correlations between miRNA expression fold change and HIV-1 log viral load reduction.
miR-30e-3p 0.821 0.034 0.522 Y [62]
miR-148b# 0.786 0.048 0.547 Y [63]
miR-30d 0.786 0.048 0.488 Y [55]
miR-589 0.786 0.048 0.431 N
doi:10.1371/journal.pone.0109220.t001
Figure 3. Visualization of miRNA and mRNA regulatory networks. (A) Plot of global miRNA and anti-HIV-1 restriction factor responses to IFN-
a/RBV treatment. Numbers in blue and red represent tallies of microRNAs and restriction factor mRNAs in each quadrant, respectively. P-values were
obtained using Fisher’s exact tests. (B) Integrative bioinformatic analyses of our miRNA data, restriction factor, MLH1 and TP53 mRNA profiles within
the context of gene regulatory networks. Ingenuity Pathway Analysis (IPA) software was implemented to create the network map.
doi:10.1371/journal.pone.0109220.g003
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We used two variables to generate the network: 1) inverse
expression relationships between a given miRNA-mRNA pair,
and 2) significant sequence homology between a given miRNA
seed region and a restriction factor 39 UTR (word size 4,
alignment length .= 5, e-value,1.0). These relationships were
interpreted as putative negative regulatory interactions between a
miRNA and mRNA. Our approach revealed a large number of
potential regulatory interactions between miRNAs and restriction
factor mRNAs (Fig. 4); 15 out of the 34 restriction factors that
were up-modulated in SHCS patients undergoing IFN-a/RBV
treatment were associated with at least 1 putative regulatory
miRNA, and 29 distinct miRNAs were involved in these predicted
relationships. To evaluate the likelihood that our network
inference strategy was revealing legitimate regulatory relation-
ships, we compared the frequencies of significant miRNA seed
sequence – mRNA 39 UTR homology hits between miRNA –
mRNA pairs with significant inverse expression relationships (35
out of 62) and pairs without inverse expression correlations (8455
out of 25,636). Using a Fisher’s Exact test, we were able to
determine that miRNA-mRNA sequence homology was observed
at a significantly higher frequency in inverse expression relation-
ships (p = 8*1026, OR = 3.2 [95% CI 1.9, 5.6]), implying that the
identified miRNA-mRNA networks might in fact play a role in
regulating restriction factor expression.
Our analyses revealed a provocative list of 22 distinct potential
miRNA regulators of TRIM21. The TRIM family contains over
60 proteins and exhibits a wide range of activities, including viral
suppression and regulation of innate and adaptive immune
responses. TRIM21 is known to play a crucial role in regulating
type I interferon production [45]. Recently, TRIM21 was
reported to recognize and degrade viruses in the cytoplasm by
binding to antibody-coated virions [46–48]. Therefore, TRIM21
acts as an intracellular arm of adaptive immunity, and serves as a
direct link between cell-intrinsic and adaptive immune processes.
Our list of predicted miRNA regulators of TRIM21 expression
warrants further investigation and may be exploited to enhance
the potent antiviral activity of TRIM21 in vivo.
Our collection of clinical samples does not allow us to evaluate
the possibility that the inclusion of ribavirin in anti-HCV therapy
and universal HCV-coinfection in our cohort may affect our
findings. However, ribavirin treatment has been previously shown
to have negligible effects against HIV-1 (56). Moreover, gene
expression profiles of HIV-1-monoinfected individuals undergoing
IFN-a monotherapy [5,49] match our gene expression data from
IFN-a/RBV-treated HIV/HCV-coinfected patients [15,16]. We
confirmed the IFN-a-mediated suppression of miR-422a by
performing an in vitro experiment in isolated peripheral blood
CD4+ T cells in the absence of ribavirin and HCV infection,
which extends our in vivo observations in IFN-a/RBV-treated
HIV/HCV-coinfected individuals. Although our principal result
involving miR-422a is not likely to have been affected by ribavirin
administration or HCV coinfection, future miRNA profiling
studies of HIV-1-monoinfected individuals undergoing IFN-a
monotherapy will complement our observations reported here.
Amongst the HIV/HCV-coinfected participants enrolled in the
Swiss HIV Cohort Study, ,85% report intravenous drug use. In
regards to potential confounding effects of IDU status on our
findings, morphine usage may affect HIV disease outcomes and
accelerate disease progression [50,51]. Moreover, in vitro studies
have demonstrated that morphine treatment increases cellular
Figure 4. Global network of putative regulatory interactions between miRNAs and anti-HIV-1 restriction factor mRNAs. miRNA and
mRNA expression data were measured in longitudinal PBMC samples from IFN-a/RBV-treated patients enrolled in the SHCS. Two variables were used
to generate the network: 1) inverse expression relationships between a given miRNA-mRNA pair (represented as a dashed line drawn between a
miRNA – mRNA pair), and 2) Significant sequence homology between a given miRNA seed region and a restriction factor 39 UTR (word size 4,
alignment length .= 5, e-value,1.0). Significant sequence homology is represented by a solid line. miRNAs are listed in blue; restriction factors are
listed in pink.
doi:10.1371/journal.pone.0109220.g004
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susceptibility to HIV infection, inhibits production of IFN-a and
IFN-b antiviral cytokines [52], and modulates the expression of
anti-HIV-1 miRNAs (miRNA-28, 125b, 150, and 382) [53].
Importantly, none of these opioid-modulated miRNAs were
modulated in response to IFN-a/RBV therapy in our study.
In summary, our data demonstrate that a specific reduction of
cellular miR-422a is associated with the suppression of HIV-1 by
IFN-a in vivo. Our tiered network analyses suggest that miR-422a
may contribute to the IFN-a-mediated suppression of HIV-1
viremia and decay of the latent reservoir via regulation of multiple
retroviral restriction factors and genes involved in p53-dependent
apoptosis and pyroptosis pathways. In addition, our global
miRNA surveys identified several miRNAs whose expression
levels were significantly correlated with HIV-1 viral load, and 29
distinct miRNAs that may regulate anti-HIV-1 restriction factor
expression in vivo. Comprehensive miRNA profiling of isolated
cellular subsets (e.g. CD4+ T cells, CD8+ T cells, B cells and
monocytes) in subsequent studies will complement these observa-
tions. The possibility exists that one or more of these identified
miRNAs may be manipulated to control HIV-1. In vivo targeting
of the liver-specific miRNA and essential HCV cofactor miR-122
by the small molecule drug ‘‘miravirsen’’ achieves up to a three-log
reduction in HCV viral load which persists indefinitely after
treatment cessation [54]. This provides a promising model, and
suggests that the development and deployment of miRNA-based
therapeutic strategies for other chronic viral pathogens including
HIV-1 is likely achievable.
To the best of our knowledge, our study is the first to
demonstrate the effect of IFN-a treatment on miRNA expression
profile in vivo, and these are the first data associating miR-422a
with HIV-1 infection. Future work should validate and extend the
translational and in silico observations reported here with detailed
in vitro analyses of miR-422a effects on HIV-1 replication and the
lifespan of HIV-1-infected cells.
Supporting Information
Figure S1 IFN-a/RBV treatment does not alter the
expression of microRNA machinery genes in vivo.
Expression of (A) DROSHA, (B) DICER1, and (C) DGCR8
miRNA machinery genes before, during, and after IFN-a/RBV
treatment. Black, light grey, and dark grey bars represent pre-
treatment, during treatment, and post-treatment expression levels,
respectively. P-values were obtained using paired Wilcoxon tests.
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IFN-a/RBV treatment).
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with p-value,0.05 (pre Rx/during Rx).
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